Furthermore, the combination of CpG and agonist anti-CD40 mAb is able to induce immune-mediated anti-tumor effects against the B78 melanoma in C57BL/6 mice (49) and augment destruction of B78 tumors in vivo when combined with an anti-GD2 mAb reactive with B78 (50). This evidence concerns the gene CD40 and neoplasm.